{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:35:06Z","timestamp":1782362106989,"version":"3.54.5"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical Research Center Program","award":["NRF-2017R1A5A2014768"],"award-info":[{"award-number":["NRF-2017R1A5A2014768"]}]},{"name":"Mid-Career Researcher Program","award":["NRF-2018R1A2A2A0523165"],"award-info":[{"award-number":["NRF-2018R1A2A2A0523165"]}]},{"name":"Ministry of Science"},{"DOI":"10.13039\/100010669","name":"ICT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>A botanical drug derived from the ethanolic extract composed of Clematis chinensis Osbeck (Ranunculaceae), Trichosanthes kirilowii Maximowicz (Cucurbitaceae) and Prunella vulgaris Linn\u00e9 (Lamiaceae) has been used to ameliorate rheumatoid arthritis as an ethical drug in Korea. In our study, we investigated the effect of this herbal complex extract (HCE) on schizophrenia-like behaviours induced by MK-801.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>HCE (30, 100 or 300 mg\/kg, p.o) was orally administered to male ICR mice to a schizophrenia-like animal model induced by MK-801. We conducted an acoustic startle response task, an open-field task, a novel object recognition task and a social novelty preference task.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>We found that a single administration of HCE (100 or 300 mg\/kg) ameliorated MK-801-induced abnormal behaviours including sensorimotor gating deficits and social or object recognition memory deficits. In addition, MK-801-induced increases in phosphorylated Akt and GSK-3\u03b2 expression levels in the prefrontal cortex were reversed by HCE (30, 100 or 300 mg\/kg).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These results imply that HCE ameliorates MK-801-induced dysfunctions in prepulse inhibition, social interactions and cognitive function, partly by regulating the Akt and GSK-3\u03b2 signalling pathways.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jphp.13199","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T08:38:53Z","timestamp":1573547933000},"page":"149-160","source":"Crossref","is-referenced-by-count":17,"title":["A botanical drug composed of three herbal materials attenuates the sensorimotor gating deficit and cognitive impairment induced by MK-801 in mice"],"prefix":"10.1093","volume":"72","author":[{"given":"Bokyung","family":"Koo","sequence":"first","affiliation":[{"name":"Department of Life and Nanopharmaceutical Science, Kyung Hee University , Seoul,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Jung","family":"Bae","sequence":"additional","affiliation":[{"name":"Department of Life and Nanopharmaceutical Science, Kyung Hee University , Seoul,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayeon","family":"Goo","sequence":"additional","affiliation":[{"name":"Department of Life and Nanopharmaceutical Science, Kyung Hee University , Seoul,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaehoon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Life and Nanopharmaceutical Science, Kyung Hee University , Seoul,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Life and Nanopharmaceutical Science, Kyung Hee University , Seoul,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mudan","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Life and Nanopharmaceutical Science, Kyung Hee University , Seoul,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Ho","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Life and Nanopharmaceutical Science, Kyung Hee University , Seoul,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungnam","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Life and Nanopharmaceutical Science, Kyung Hee University , Seoul,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo Yun","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Life and Nanopharmaceutical Science, Kyung Hee University , Seoul,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk Woo","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Life and Nanopharmaceutical Science, Kyung Hee University , Seoul,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Sik","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Life and Nanopharmaceutical Science, Kyung Hee University , Seoul,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1602-355X","authenticated-orcid":false,"given":"Jong Hoon","family":"Ryu","sequence":"additional","affiliation":[{"name":"Department of Life and Nanopharmaceutical Science, Kyung Hee University , Seoul,","place":["Korea"]},{"name":"Department of Oriental Pharmaceutical Science, Kyung Hee University , Seoul,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,1,1]]},"reference":[{"key":"2024103012353466000_jphp13199-cit-0001","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/schbul\/sbp017","article-title":"What we know: findings that every theory of schizophrenia should explain","volume":"35","author":"MacDonald","year":"2009","journal-title":"Schizophr Bull"},{"key":"2024103012353466000_jphp13199-cit-0002","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"van Os","year":"2009","journal-title":"Lancet"},{"key":"2024103012353466000_jphp13199-cit-0003","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Mol Psychiatry"},{"key":"2024103012353466000_jphp13199-cit-0004","article-title":"Review of the safety of second-generation antipsychotics: are they really \"atypically\" safe for youth and adults?","volume":"14","author":"Briles","year":"2012","journal-title":"Prim Care Companion CNS Disord"},{"key":"2024103012353466000_jphp13199-cit-0005","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"2024103012353466000_jphp13199-cit-0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnpbp.2012.10.008","article-title":"Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia","volume":"42","author":"Anderson","year":"2013","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2024103012353466000_jphp13199-cit-0007","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4088\/JCP.09m05117yel","article-title":"Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial","volume":"71","author":"Laan","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"2024103012353466000_jphp13199-cit-0008","first-page":"31","article-title":"COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence","volume":"11","author":"Muller","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"2024103012353466000_jphp13199-cit-0009","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.schres.2010.04.015","article-title":"Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment","volume":"121","author":"Muller","year":"2010","journal-title":"Schizophr Res"},{"key":"2024103012353466000_jphp13199-cit-0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00406-004-0548-4","article-title":"Clinical effects of COX-2 inhibitors on cognition in schizophrenia","volume":"255","author":"Muller","year":"2005","journal-title":"Eur Arch Psy Clin Neurosci"},{"key":"2024103012353466000_jphp13199-cit-0011","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1002\/ptr.4929","article-title":"Prunella vulgaris attenuates prepulse inhibition deficit and attention disruption induced by MK-801 in mice","volume":"27","author":"Park","year":"2013","journal-title":"Phytother Res"},{"key":"2024103012353466000_jphp13199-cit-0012","first-page":"Unit 8.7","article-title":"Measurement of startle response, prepulse inhibition, and habituation","volume":"Chapter 8","author":"Geyer","year":"2001","journal-title":"Curr Protoc Neurosci"},{"key":"2024103012353466000_jphp13199-cit-0013","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1038\/srep08502","article-title":"Toll-like receptor-2 deficiency induces schizophrenia-like behaviors in mice","volume":"5","author":"Park","year":"2015","journal-title":"Sci Rep"},{"key":"2024103012353466000_jphp13199-cit-0014","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/0269881116672098","article-title":"Swertisin ameliorates pre-pulse inhibition deficits and cognitive impairment induced by MK-801 in mice","volume":"31","author":"Oh","year":"2017","journal-title":"J Psychopharmacol"},{"key":"2024103012353466000_jphp13199-cit-0015","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III\u2013the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr Bull"},{"key":"2024103012353466000_jphp13199-cit-0016","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.mehy.2013.03.013","article-title":"A serotonin hypothesis of schizophrenia","volume":"80","author":"Eggers","year":"2013","journal-title":"Med Hypotheses"},{"key":"2024103012353466000_jphp13199-cit-0017","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"2024103012353466000_jphp13199-cit-0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059395","article-title":"Glutamatergic dysbalance and oxidative stress in in vivo and in vitro models of psychosis based on chronic NMDA receptor antagonism","volume":"8","author":"Genius","year":"2013","journal-title":"PLoS ONE"},{"key":"2024103012353466000_jphp13199-cit-0019","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/YCO.0000000000000152","article-title":"Drug development in schizophrenia: are glutamatergic targets still worth aiming at?","volume":"28","author":"Goff","year":"2015","journal-title":"Curr Opin Psychiatry"},{"key":"2024103012353466000_jphp13199-cit-0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881114563634","article-title":"Glutamate and dopamine in schizophrenia: an update for the 21st century","volume":"29","author":"Howes","year":"2015","journal-title":"J Psychopharmacol"},{"key":"2024103012353466000_jphp13199-cit-0021","first-page":"253","article-title":"Immunology in schizophrenic disorders","volume":"78","author":"Muller","year":"2007","journal-title":"Nervenarzt"},{"key":"2024103012353466000_jphp13199-cit-0022","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.neubiorev.2008.03.012","article-title":"Models of schizophrenia in humans and animals based on inhibition of NMDA receptors","volume":"32","author":"Bubenikova-Valesova","year":"2008","journal-title":"Neurosci Biobehav Rev"},{"key":"2024103012353466000_jphp13199-cit-0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4062\/biomolther.2012.20.1.001","article-title":"Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments","volume":"20","author":"Rubio","year":"2012","journal-title":"Biomol Ther (Seoul)"},{"key":"2024103012353466000_jphp13199-cit-0024","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0006-3223(99)00148-1","article-title":"Impaired prepulse inhibition of acoustic startle in schizophrenia","volume":"47","author":"Parwani","year":"2000","journal-title":"Biol Psychiatry"},{"key":"2024103012353466000_jphp13199-cit-0025","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1476-5381.2011.01386.x","article-title":"Animal models of schizophrenia","volume":"164","author":"Jones","year":"2011","journal-title":"Br J Pharmacol"},{"key":"2024103012353466000_jphp13199-cit-0026","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.euroneuro.2013.10.001","article-title":"Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophrenia","volume":"24","author":"Barnes","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"2024103012353466000_jphp13199-cit-0027","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1254\/jphs.14R02CR","article-title":"Behavioral phenotypes for negative symptoms in animal models of schizophrenia","volume":"126","author":"Miyamoto","year":"2014","journal-title":"J Pharmacol Sci"},{"key":"2024103012353466000_jphp13199-cit-0028","first-page":"1313","article-title":"Brain in flames \u2013 animal models of psychosis: utility and limitations","volume":"11","author":"Mattei","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2024103012353466000_jphp13199-cit-0029","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0361-9230(90)90241-Q","article-title":"Startle response models of sensorimotor gating and habituation deficits in schizophrenia","volume":"25","author":"Geyer","year":"1990","journal-title":"Brain Res Bull"},{"key":"2024103012353466000_jphp13199-cit-0030","doi-asserted-by":"crossref","first-page":"472","DOI":"10.55782\/ane-2013-1953","article-title":"Animal models of schizophrenia: developmental preparation in rats","volume":"73","author":"Ratajczak","year":"2013","journal-title":"Acta Neurobiol Exp (Wars)"},{"key":"2024103012353466000_jphp13199-cit-0031","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fnmol.2012.00033","article-title":"AKT\/GSK3 signaling pathway and schizophrenia","volume":"5","author":"Emamian","year":"2012","journal-title":"Front Mol Neurosci"},{"key":"2024103012353466000_jphp13199-cit-0032","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s11064-006-9128-5","article-title":"Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics","volume":"32","author":"Jope","year":"2007","journal-title":"Neurochem Res"},{"key":"2024103012353466000_jphp13199-cit-0033","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.neuron.2014.11.007","article-title":"A dopamine D2 receptor-DISC1 protein complex may contribute to antipsychotic-like effects","volume":"84","author":"Su","year":"2014","journal-title":"Neuron"},{"key":"2024103012353466000_jphp13199-cit-0034","doi-asserted-by":"crossref","first-page":"19581","DOI":"10.1038\/srep19581","article-title":"Olanzapine prevents the PCP-induced reduction in the neurite outgrowth of prefrontal cortical neurons via NRG1","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep"},{"key":"2024103012353466000_jphp13199-cit-0035","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1017\/S1461145706006869","article-title":"The effects of repeated administrations of MK-801 on ERK and GSK-3beta signalling pathways in the rat frontal cortex","volume":"10","author":"Seo","year":"2007","journal-title":"Int J Neuropsychopharmacol"},{"key":"2024103012353466000_jphp13199-cit-0036","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/npp.2011.12","article-title":"Group II metabotropic glutamate receptor agonist ameliorates MK801-induced dysfunction of NMDA receptors via the Akt\/GSK-3beta pathway in adult rat prefrontal cortex","volume":"36","author":"Xi","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"2024103012353466000_jphp13199-cit-0037","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/npp.2014.38","article-title":"Clozapine acts as an agonist at serotonin 2A receptors to counter MK-801-induced behaviors through a betaarrestin2-independent activation of Akt","volume":"39","author":"Schmid","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"2024103012353466000_jphp13199-cit-0038","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3389\/fnins.2015.00372","article-title":"The role of inflammation in schizophrenia","volume":"9","author":"Muller","year":"2015","journal-title":"Front Neurosci"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jphp.13199","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jphp.13199","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/72\/1\/149\/60226668\/jphp13199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/72\/1\/149\/60226668\/jphp13199.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T18:03:50Z","timestamp":1730311430000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/72\/1\/149\/6122094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,1]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.13199","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2020,1,1]]}}}